Want to see TECH full AI Analyst Report?
TECH Stock Chart & Stats
$71.60
$0.18(0.25%)
At close: 4:00 PM EDT
$71.60
$0.18(0.25%)
Day’s Range― - ―
52-Week Range$43.20 - $72.62
Previous CloseN/A
Volume1.43M
Average Volume (3M)6.36M
Market Cap
$11.32B
Enterprise Value$11.12K
Total Cash (Recent Filing)$264.71M
Total Debt (Recent Filing)$274.15M
Price to Earnings (P/E)61.8
Beta0.82
Next Earnings
Nov 03, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)1.17
Shares Outstanding156,568,760
10 Day Avg. Volume2,893,193
30 Day Avg. Volume6,358,642
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)5.23
Price to Sales (P/S)9.07
P/FCF Ratio41.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$72.11Price Target Upside0.71% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)2.06
Revenue Forecast (FY)$1.27B
Bulls Say, Bears Say
Bulls Say
Differentiated Spatial Biology PlatformRapid COMET adoption, a record backlog, and expansion into China indicate a scalable technology platform. Its role in multiomic workflows can deepen customer integration and support recurring instrument, consumable, and service revenue.
Strong Cash Generation And Balance SheetLow leverage and consistently strong operating cash flow provide financial flexibility for research investment, acquisitions, and resilience through uneven biotech demand. Healthy cash conversion also supports the company’s ability to fund operations without heavy borrowing.
Recurring Consumables And Workflow RevenueThe combination of consumable reagents, diagnostic products, and recurring purchases tied to installed instruments creates repeat customer demand. This workflow-based model can improve revenue durability as laboratories continue research and testing activity.
Bears Say
Biotech Spending WeaknessExposure to early-stage biotech makes demand sensitive to funding cycles. Even with improved financing, management cites a two-to-three-quarter lag before spending recovers, creating a sustained risk to reagent and assay growth over the next several months.
Volatile Profitability And Cash Flow MomentumThe recovery in profitability is encouraging, but margins remain below prior peaks and cash flow growth has been uneven. Product mix, volume deleverage, and operating variability could limit the sustainability of earnings improvements.
Pending Merck Acquisition Execution RiskThe Merck transaction may broaden scale and capabilities, but completion remains dependent on multiple approvals through a long-stop date in March 2027. Delays, regulatory remedies, or failure to close could prolong strategic uncertainty and disrupt planning.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $43.20 and its highest was $72.62 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $11.32B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Nov 03, 2026 which is in 72 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Aug 12, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.519 by $0.001.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.44%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.44.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 156,568,760 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.52 in its last earnings report, beating expectations of $0.519. Following the earnings report the stock price went up 0.111%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Techne Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$72.11 (0.71% Upside)
$72.11 (0.71% Upside)
Blogger Sentiment
Neutral
TECH Sentiment 83%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 4.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.19%
12-Months-Change
Fundamentals
Return on Equity
0.44%
Trailing 12-Months
Asset Growth
1.13%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
TECH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong execution in high-value growth vectors (Spatial Biology/COMET, GMP proteins excl. timing impacts, Proteomic Analysis instruments, large pharma strength and four consecutive quarters of China growth), solid sequential margin improvement and robust cash generation. Offsetting these positives were a 2% organic revenue decline, continued weakness in emerging/early-stage biotech spending, timing headwinds from two fast-track cell therapy customers and an OEM order, and YoY mix-related margin pressure. Management expects near-term organic revenue to be roughly flat but positions the business for an inflection in fiscal 2027 as funding improvements translate to customer spending.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
-0.08% Intersegment
0.34% Other revenue
TECH Stock 12 Month Forecast
Average Price Target
$72.11
▲(0.71% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.32% Insiders
45.08% Mutual Funds
13.35% Other Institutional Investors
13.26% Public Companies and
Individual Investors